Fentanyl Citrate | Cephalon | ||
EQ 0.1, 0.2, 0.3, 0.4, 0.6, 0.8 mg ; Tablet, Buccal, Sublingual |
Less Than $1000 mn
|
||
Less Than 5
|
More Than 5
|
||
None | None | ||
Less Than 5
|
None | ||
Indicated for the management of breakthrough pain in cancer patients 18 years of age and older who are already receiving and who are tolerant to around-the-clock opioid therapy for their underlying persistent cancer pain. | |||
Yes
|
Fentora | Patent 1 | Patent 2 | Patent 3 | Patent 4 |
---|---|---|---|---|
****** | - | - | - | - |
**** (****) | - | - | - | - |
***** | ******* | ******* | ******* | ******* |
Company | FTF Status / 180 days exclusivity | 30-Months stay | Current Litigation Status | Current Approval Status | Likelihood of launch |
---|---|---|---|---|---|
****** | ******** ** **** | -**- | -**- | -**- | -**- |
**** (****) | **** ******** ******** | -**- | -**- | -**- | -**- |
***** | ** \ ** | *** **, **** | ******* | **** | ****** **** ******** |